二氢吡啶类钙拮抗剂主要作用机制是抑制平滑肌 L-型钙通道 ,降低胞内钙浓度 ,从而减弱平滑肌的舒张作用。然而 ,已有证据表明 ,二氢吡啶类能诱发 NO从各类血管内皮释放。另外 ,二氢吡啶类对 NO合酶抑制剂的灵敏度也得以证实。双重模式的发现 ,即通过抑制平滑肌 L-型钙通道引起的直接的舒张效应和通过血管内皮 NO释放引起的间接的舒张效应 ,有助于理解二氢吡啶类钙拮抗剂的抗高血压效应 ,及在某些血管区域的选择性效应。血管内皮及血小板 NO的释放 ,对某些二氢吡啶类的抗动脉粥样硬化作用和抗血栓形成作用有利 Dihydropyridine calcium antagonists the main mechanism of action is to inhibit L-type calcium channel smooth muscle, reducing intracellular calcium concentration, thereby reducing the smooth muscle relaxation. However, there is evidence that dihydropyridines induce NO release from various types of vascular endothelium. In addition, the sensitivity of dihydropyridines to NO synthase inhibitors was also demonstrated. The discovery of the dual model helps to understand the antihypertensive effect of dihydropyridine calcium antagonists by inhibiting the direct diastolic effect of smooth muscle L-type calcium channels and the indirect relaxation effect by the release of endothelium NO, And selective effects in certain vascular areas. The release of NO from the vascular endothelium and platelets is beneficial for the anti-atherosclerotic and antithrombotic effects of some dihydropyridines